The overall tone shows a balanced acknowledgment of the article’s analysis, with phrases like ‘assessment challenges’ and ‘responsiveness’ indicating interest in improving evaluation processes. The mentions of 'uncertainty' and 'inconsistent approaches' reflect engagement with the complexities faced by HTA bodies, while the moderate agreement score captures general consensus on the need for enhanced methodologies, all contributing to the perceived impact of the publication on future assessment practices.
AgreementModerate agreement
Most discussions acknowledge that HTA bodies face significant challenges with cell and gene therapies, recognizing the article's insights into current responses and need for improvements.
InterestModerate interest
The discussions demonstrate moderate interest, focusing on understanding assessment responses and the implications for healthcare evaluation, without deep technical engagement.
EngagementModerate engagement
Participants reference specific challenges such as unvalidated endpoints and economic uncertainty, indicating a reasonable level of engagement and curiosity about evaluation methods.
ImpactModerate impact
There is a shared view that the publication's findings are influential, highlighting the potential for improved decision-making processes in health technology assessments.
Abstract in brief
The research aimed to understand the evidence needed for assessing the clinical and cost-effectiveness of cell and gene therapies and how these are recognized in health technology assessments (HTA) processes.
A literature review analyzed 46 HTA reports on 9 products in various jurisdictions, revealing positive reactions to evidence related to rare diseases, substantial health gains, and alternative payment models; while they were critical of unvalidated endpoints, inadequate trial reporting, and uncertainty in economic estimates.
The findings indicate that HTA bodies have inconsistent approaches to evaluating cell and gene therapies, suggesting improvements in decision-making and additional analyses to better handle the complexities these therapies present.
#Produccioncientifica @EASPsalud How are health technology assessment bodies responding to the assessment challenges posed by cell and #genetherapy? @jaime_net #EASPdivulga #CellTherapy #HealthTechnologyAssessment https://t.co/obvmXQlxSQ https://t.co/ZZYoMqnnvW
May 16, 2023 · 3 likes · 1 share · 4,737 followersView post →
ES
Escuela Andaluza SP
@EASPsalud · X
RT @BiblioEASP: #Produccioncientifica @EASPsalud How are health technology assessment bodies responding to the assessment challenges posed…
May 16, 2023 · 1 share · 18,684 followersView post →
This video explores how health technology assessment bodies are addressing the assessment challenges posed by cell and gene therapies, highlighting evidence needs, jurisdictional differences, and the importance of…
RT @BiblioEASP: #Produccioncientifica @EASPsalud How are health technology assessment bodies responding to the assessment challenges posed…
May 16, 2023 · 1 share · 18,684 followersView post →
BE
Biblioteca EASP
@BiblioEASP · X
#Produccioncientifica @EASPsalud How are health technology assessment bodies responding to the assessment challenges posed by cell and #genetherapy? @jaime_net #EASPdivulga #CellTherapy #HealthTechnologyAssessment https://t.co/obvmXQlxSQ https://t.co/ZZYoMqnnvW
May 16, 2023 · 3 likes · 1 share · 4,737 followersView post →
M
MyJournals
@myjournals · X
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? https://t.co/DSaCKcVcuB
Iqvia Institute Cagt Report 03 24 Forweb | PDF | Gene Therapy | Cell ...
News
https://doi.org/10.1186/s12913-023-09494-5 87. Gozzo L, Romano GL, Romano F, Brancati S, Longo L, Vitale DC, et al. Health technology assessment of advanced ...